Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.
Saved in:
| Title: | Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H. |
|---|---|
| Authors: | Salama AKS; Duke University, Durham, NC., Wang V; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistical Center, Boston, MA., Macrae ER; Columbus Oncology and Hematology Associates, Columbus, OH., Park JI; Medical College of Wisconsin, Milwaukee, WI., Chen HX; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Gray RJ; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistical Center, Boston, MA., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton D; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, CA., Armstrong DK; Johns Hopkins University, Baltimore, MD., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; University of Texas Southwestern Medical Center, Dallas, TX., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Clinic, NCI, Bethesda, MD., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA. |
| Source: | JCO precision oncology [JCO Precis Oncol] 2026 Jan; Vol. 10, pp. e2500338. Date of Electronic Publication: 2026 Jan 14. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
